Stefan Dubel,
Full Professor and Director,
Technische Universität Braunschweig
Dr. Stefan Dübel is full Professor of Biotechnology and Director of the respective department at the Technische Universität Braunschweig, Germany (http://www.bbt.tu-bs.de/Biotech). He further serves as director of the technology transfer unit "Centre for Molecular Engineering" of iTUBSmbH and as consultant to biotech / pharma companies and US/EU goverment institutions. He initiated the "Antibody factory" of the German National Gemome Research Network and is editor of the four volume "Handbook of Therapeutic Antibodies" and other antibody engineering books. He is co-founder of several biotech companies, most recently of the human antibody discovery and antibody engineering company Yumab GmbH (www.yumab.com).
After obtaining his Ph.D. from the Universitiy of Heidelberg, in 1989 he joined the German Cancer Research Center (DKFZ) where he co-pioneered in vitro antibody selection technologies, resulting in several key inventions including antibody phage display (e.g. US Patent 5849500), human antibody libraries (e.g. US6319690) and antibody libraries with randomised CDRs (e.g. US Patent 5840479). His lab continued to contribute to multiple topics related to human antibody engineering, phage display and in vitro evolution, e.g. Hyperphage technology (2001), ORFeome display (2006), and targeted RNases for cancer therapy (1995/2008). Other achievements include the developed the world's first protein knock down mouse using intrabodies (2014), and a universal allosteric switch module for antibody affinity (2017). His work resulted in >200 publications and >25 patent applications.
New Ways For Human Antibodies - From Intracellular Applications to Switchable Affinity
Friday, 25 May 2018 at 14:30
Add to Calendar ▼2018-05-25 14:30:002018-05-25 15:30:00Europe/LondonNew Ways For Human Antibodies - From Intracellular Applications to Switchable AffinityStem Cells and Antibodies in Drug Discovery Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
While the generation and optimization of human antibodies by phage display today allows to design fine specificity and kinetic parameters in detail, and CAR-T-cells, ADCs, bi-specific antibodies and many others creative derivatives of the original IgG molecule are approved or in clinical studies, the antibody molecule still offers many opportunities for new and innovative applications. The access of intracellular antigens with biologicals would add a huge target space to therapeutic antibodies. We used intra-bodies in the first protein knock down mouse to demonstrate the in vivo function of this principle, but also analysed many strategies to insert antibodies from the outside of the cell. On another end, using cyclic mutants of human calmodulin as an allosteric effector module, antigen binding affinity of different antibodies could be regulated. This allosteric effect was demonstrated for five different scFv fragments under physiological conditions on living cells without the need of pH or ion concentration changes.
Add to Calendar ▼2018-05-24 00:00:002018-05-25 00:00:00Europe/LondonStem Cells and Antibodies in Drug Discovery Europe 2018Stem Cells and Antibodies in Drug Discovery Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-05-25 14:30:002018-05-25 15:30:00Europe/LondonNew Ways For Human Antibodies - From Intracellular Applications to Switchable AffinityStem Cells and Antibodies in Drug Discovery Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
